

Dieter Hoelzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11286698/publications.pdf>

Version: 2024-02-01

177
papers

19,682
citations

14655

66
h-index

11052

137
g-index

182
all docs

182
docs citations

182
times ranked

15398
citing authors

#	ARTICLE	IF	CITATIONS
1	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL. <i>New England Journal of Medicine</i> , 2006, 354, 2542-2551.	27.0	1,253
2	Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. <i>Lancet</i> , 2013, 381, 1203-1210.	13.7	1,240
3	Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. <i>Nature Medicine</i> , 2006, 12, 401-409.	30.7	1,129
4	Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 2493-2498.	1.6	819
5	Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. <i>Nature Medicine</i> , 2010, 16, 198-204.	30.7	727
6	Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 4134-4140.	1.6	577
7	A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. <i>Blood</i> , 2002, 100, 1965-1971.	1.4	534
8	Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. <i>Blood</i> , 2006, 107, 1116-1123.	1.4	488
9	Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i> , 2012, 120, 5185-5187.	1.4	435
10	Modern Therapy of Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 532-543.	1.6	425
11	Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3383-3389.	1.6	412
12	Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. <i>Blood</i> , 2012, 119, 6226-6233.	1.4	410
13	Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. <i>Blood</i> , 2012, 120, 1868-1876.	1.4	405
14	Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. <i>Blood</i> , 2012, 120, 2032-2041.	1.4	381
15	Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2889-2896.	1.6	351
16	Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). <i>Blood</i> , 2006, 108, 1469-1477.	1.4	307
17	Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. <i>Blood</i> , 2002, 99, 1536-1543.	1.4	302
18	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. <i>Blood</i> , 2016, 128, 774-782.	1.4	243

#	ARTICLE	IF	CITATIONS
19	Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. <i>Blood</i> , 2014, 124, 3870-3879.	1.4	236
20	Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. <i>Blood</i> , 2007, 109, 910-915.	1.4	226
21	Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. <i>Blood</i> , 2002, 99, 1860-1862.	1.4	225
22	Adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 1165-1176.	4.1	225
23	Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. <i>Blood</i> , 2002, 100, 3553-3560.	1.4	219
24	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). <i>Blood</i> , 2007, 110, 727-734.	1.4	218
25	Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). <i>Cancer</i> , 2007, 109, 2068-2076.	4.1	214
26	Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. <i>Lancet</i> , The, 2002, 359, 481-486.	13.7	203
27	Treatment of Adult Acute Lymphoblastic Leukemia. <i>Seminars in Hematology</i> , 2009, 46, 64-75.	3.4	199
28	Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. <i>Blood</i> , 2002, 99, 4379-4385.	1.4	195
29	Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2004, 22, 2816-2825.	1.6	193
30	Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). <i>Blood</i> , 2005, 106, 458-463.	1.4	190
31	Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. <i>Blood</i> , 2013, 121, 4749-4752.	1.4	181
32	Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2024-2034.	1.6	176
33	Valproic Acid Stimulates Proliferation and Self-renewal of Hematopoietic Stem Cells. <i>Cancer Research</i> , 2005, 65, 2537-2541.	0.9	175
34	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2010, 116, 614-616.	1.4	170
35	TREATMENT OF ADULT ALL ACCORDING TO PROTOCOLS OF THE GERMAN MULTICENTER STUDY GROUP FOR ADULT ALL (GMALL). <i>Hematology/Oncology Clinics of North America</i> , 2000, 14, 1307-1325.	2.2	167
36	High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. <i>Blood</i> , 2011, 118, 3504-3511.	1.4	158

#	ARTICLE	IF	CITATIONS
37	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	3.5	154
38	Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. <i>Haematologica</i> , 2002, 87, 33-43.	3.5	146
39	Lymphoblastic lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 330-343.	4.4	141
40	Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have <i>IGH-CRLF2</i> and <i>JAK2</i> mutations, persistence of minimal residual disease and poor prognosis. <i>Haematologica</i> , 2017, 102, 130-138.	3.5	136
41	Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. <i>Blood</i> , 2008, 112, 918-919.	1.4	125
42	High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma. <i>Cancer</i> , 2008, 113, 117-125.	4.1	122
43	IL-18 Activates STAT3 in the Natural Killer Cell Line 92, Augments Cytotoxic Activity, and Mediates IFN- γ Production by the Stress Kinase p38 and by the Extracellular Regulated Kinases p44 erk-1 and p42 erk-2 . <i>Journal of Immunology</i> , 2000, 165, 1307-1313.	0.8	121
44	Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. <i>Blood</i> , 2003, 102, 659-661.	1.4	120
45	Treatment of Adult Acute Lymphoblastic Leukemia. Hematology American Society of Hematology Education Program, 2006, 2006, 133-141.	2.5	114
46	Treatment of Adult ALL According to Protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2008, , 167-176.		111
47	Ex Vivo Induction of Apoptosis in Lymphocytes Is Mediated by Oxidative Stress: Role for Lymphocyte Loss in HIV Infection. <i>Free Radical Biology and Medicine</i> , 1997, 22, 775-785.	2.9	106
48	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	2.4	106
49	High Expression of the ETS Transcription Factor ERG Predicts Adverse Outcome in Acute T-Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2006, 24, 4714-4720.	1.6	100
50	PIC-1/SUMO-1-Modified PML-Retinoic Acid Receptor β Mediates Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia. <i>Molecular and Cellular Biology</i> , 1999, 19, 5170-5178.	2.3	98
51	Mutational spectrum of adult T-ALL. <i>Oncotarget</i> , 2015, 6, 2754-2766.	1.8	98
52	Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study) Tj ETQq0 0 0 TgBT /Overlock 10 T	1.4	96
53	Acute Lymphoblastic Leukemia. Hematology American Society of Hematology Education Program, 2002, 2002, 162-192.	2.5	92
54	Low <i>ERG</i> and <i>BAALC</i> Expression Identifies a New Subgroup of Adult Acute T-Lymphoblastic Leukemia With a Highly Favorable Outcome. <i>Journal of Clinical Oncology</i> , 2007, 25, 3739-3745.	1.6	92

#	ARTICLE	IF	CITATIONS
55	The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 208-213.	0.8	89
56	Â-Catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. <i>Blood</i> , 2004, 103, 3535-3543.	1.4	88
57	FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2013, 8, e53190.	2.5	87
58	Enhanced production of IL-18 in butyrate-treated intestinal epithelium by stimulation of the proximal promoter region. <i>European Journal of Immunology</i> , 2002, 32, 2635-2643.	2.9	85
59	Chemoimmunotherapy in acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2012, 26, 25-32.	5.7	84
60	Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 21-27.	0.4	83
61	Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1996, 95, 678-691.	2.5	81
62	Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR \hat{A} -positive leukemic stem cells. <i>Haematologica</i> , 2007, 92, 323-331.	3.5	81
63	Lymphoblastic lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 304-317.	4.4	81
64	Recent approaches in acute lymphoblastic leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 36, 49-58.	4.4	78
65	Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. <i>Annals of Hematology</i> , 2004, 83, 201-205.	1.8	76
66	Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 241-246.	3.5	72
67	Hematopoietic stem cell involvement in BCR-ABL1 \hat{A} -positive ALL as a potential mechanism of resistance to blinatumomab therapy. <i>Blood</i> , 2017, 130, 2027-2031.	1.4	72
68	Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl \hat{A} -positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). <i>Blood</i> , 2003, 101, 85-90.	1.4	70
69	Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. <i>Haematologica</i> , 2009, 94, 1383-1390.	3.5	70
70	T-Cell Lymphoblastic Lymphoma and T-Cell Acute Lymphoblastic Leukemia: A Separate Entity?. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S214-S221.	1.4	65
71	Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6362-6367.	1.4	64
72	Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. <i>Annals of Hematology</i> , 2013, 92, 747-758.	1.8	61

#	ARTICLE	IF	CITATIONS
73	Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. <i>Leukemia Research</i> , 2001, 25, 333-338.	0.8	58
74	High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 3737-3744.	1.4	58
75	Acute Lymphoblastic Leukemia – Progress in Children, Less in Adults. <i>New England Journal of Medicine</i> , 1993, 329, 1343-1344.	27.0	57
76	Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. <i>Haematologica</i> , 2011, 96, 238-244.	3.5	57
77	Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. <i>Blood</i> , 2018, 131, 1464-1475.	1.4	57
78	Advances in the Treatment of Chronic Granulomatous Disease by Gene Therapy. <i>Current Gene Therapy</i> , 2007, 7, 155-161.	2.0	56
79	Recent approaches in acute lymphoblastic leukemia in adults. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, 6, 114-141.	0.1	54
80	NUP214-ABL1 in adult T-ALL: the GMALL study group experience. <i>Blood</i> , 2006, 108, 3556-3559.	1.4	54
81	CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). <i>Blood</i> , 2005, 106, 4054-4056.	1.4	53
82	Transcriptional Profiling of Human Hematopoiesis During In Vitro Lineage-Specific Differentiation. <i>Stem Cells</i> , 2005, 23, 1154-1169.	3.2	50
83	Myelodysplastic syndromes. <i>The Hematology Journal</i> , 2004, 5, 1-8.	1.4	49
84	Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. <i>Blood</i> , 2004, 103, 1495-1498.	1.4	49
85	Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 655-660.	1.3	48
86	Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene Therapy. <i>Molecular Therapy</i> , 2011, 19, 2031-2039.	8.2	48
87	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	1.5	48
88	Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. <i>Haematologica</i> , 2007, 92, 542-545.	3.5	45
89	Treatment of lymphoblastic lymphoma in adults. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 713-728.	1.7	43
90	Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 243-249.	2.5	43

#	ARTICLE	IF	CITATIONS
91	Targeted therapies in the treatment of Philadelphia chromosome ⁺ positive acute lymphoblastic leukemia. <i>Seminars in Hematology</i> , 2002, 39, 32-37.	3.4	41
92	Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. <i>Biochemical Pharmacology</i> , 2003, 66, 711-724.	4.4	41
93	Atypical BCR-ABL mRNA transcripts in adult Acute lymphoblastic leukemia. <i>Haematologica</i> , 2007, 92, 1699-1702.	3.5	39
94	Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 942-949.	3.5	39
95	MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia. <i>Leukemia Research</i> , 2013, 37, 647-656.	0.8	39
96	Changing Incidence and Survival in Patients with AIDS-Related Non-Hodgkin's Lymphomas in the Era of Highly Active Antiretroviral Therapy (HAART). <i>Leukemia and Lymphoma</i> , 2001, 41, 105-116.	1.3	37
97	Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. <i>Blood</i> , 2003, 102, 2985-2993.	1.4	37
98	CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. <i>Haematologica</i> , 2009, 94, 224-229.	3.5	36
99	Increase in CD4 ⁺ T cells in the peripheral blood and bone marrow as a selective feature of HIV-1 but not other virus infections. <i>British Journal of Haematology</i> , 1998, 100, 728-734.	2.5	35
100	DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. <i>Experimental Hematology</i> , 2007, 35, 712-723.	0.4	34
101	Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2341-2348.	1.3	34
102	Expression of interleukin-18 receptor in fibroblast-like synoviocytes. <i>Arthritis Research</i> , 2002, 4, 139.	2.0	31
103	Novel antibody-based therapy for acute lymphoblastic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 701-713.	1.7	27
104	Alteration of c-mpl ⁺ mediated signal transduction in CD34 ⁺ cells from patients with myelodysplastic syndromes. <i>Experimental Hematology</i> , 2000, 28, 1158-1163.	0.4	26
105	Risk-adapted treatment according to minimal residual disease in adult ALL. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 639-652.	1.7	26
106	Expression of interleukin 15 in primary adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 387-392.	4.1	26
107	High Survival Rate in Adult Burkitt's Lymphoma/Leukemia and Diffuse Large B-Cell Lymphoma with Mediastinal Involvement.. <i>Blood</i> , 2007, 110, 518-518.	1.4	26
108	AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective. <i>Leukemia and Lymphoma</i> , 2006, 47, 1872-1880.	1.3	25

#	ARTICLE	IF	CITATIONS
109	Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. <i>Current Opinion in Oncology</i> , 2013, 25, 701-706.	2.4	24
110	Loss-of-function but not dominant-negative intragenic <i>IKZF1</i> deletions are associated with an adverse prognosis in adult <i>BCR-ABL</i> -negative acute lymphoblastic leukemia. <i>Haematologica</i> , 2017, 102, 1739-1747.	3.5	24
111	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the 18 F-Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial. <i>Annals of Hematology</i> , 2019, 98, 897-907.	1.8	24
112	<i>In vitro</i> improvement of bone marrow-derived hematopoietic colony formation in HIV-positive patients by alpha-tocopherol and erythropoietin. <i>European Journal of Haematology</i> , 1994, 53, 201-206.	2.2	23
113	Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2004, 104, 2732-2732.	1.4	23
114	Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. <i>Oncogene</i> , 2003, 22, 6900-6908.	5.9	22
115	Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. <i>Annals of Hematology</i> , 2009, 88, 1199-1205.	1.8	22
116	Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 6-16.	2.4	22
117	Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003. <i>Blood</i> , 2007, 110, 12-12.	1.4	22
118	Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. <i>Experimental Hematology</i> , 1999, 27, 395-400.	0.4	21
119	Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571. <i>Clinical Cancer Research</i> , 2006, 12, 2025-2031.	7.0	21
120	Germline variants in <i>IKZF1</i> , <i>ARID5B</i> , and <i>CEBPE</i> as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group. <i>Haematologica</i> , 2014, 99, e23-e25.	3.5	21
121	Epigenetic regulation of <i>PAX5</i> expression in acute T-cell lymphoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 614-619.	0.8	20
122	The Integrity of the Charged Pocket in the BTB/POZ Domain Is Essential for the Phenotype Induced by the Leukemia-Associated t(11;17) Fusion Protein <i>PLZF/RARα</i> . <i>Cancer Research</i> , 2005, 65, 6080-6088.	0.9	19
123	Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies. <i>Current Pharmaceutical Design</i> , 2006, 12, 111-128.	1.9	19
124	Personalized medicine in adult acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 855-858.	3.5	19
125	Clonal expansion of γ 3/ δ 3-expressing $\gamma\delta$ T cells in an HIV-1/2-negative patient with CD4 T-cell deficiency. <i>British Journal of Haematology</i> , 1997, 96, 266-271.	2.5	18
126	Differential Effects of Histone Deacetylase Inhibitors on Interleukin-18 Gene Expression in Myeloid Cells. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 937-943.	2.1	18

#	ARTICLE	IF	CITATIONS
127	Regulation of human IL-18 gene expression: interaction of PU.1 with GC-box binding protein is involved in human IL-18 expression in myeloid cells. <i>European Journal of Immunology</i> , 2004, 34, 817-826.	2.9	18
128	Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients. <i>Journal of Hematology and Oncology</i> , 2014, 7, 51.	17.0	18
129	Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. <i>Hematological Oncology</i> , 2020, 38, 244-256.	1.7	18
130	In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. <i>Pharmacological Research</i> , 2006, 53, 49-61.	7.1	17
131	Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2020, 104, 299-309.	2.2	17
132	Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.. <i>Blood</i> , 2008, 112, 1926-1926.	1.4	17
133	Asparaginase activities during intensified treatment with pegylated <i>E. coli</i> asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 138-145.	1.3	16
134	Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).. <i>Blood</i> , 2005, 106, 150-150.	1.4	16
135	Involvement of the <i>MLL</i> gene in adult T-lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1114-1124.	2.8	14
136	Multidrug resistance-associated protein 4 (MRP4) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 5400-5401.	1.4	13
137	Anti-CD22 therapy in acute lymphoblastic leukaemia. <i>Lancet Oncology</i> , The, 2012, 13, 329-331.	10.7	11
138	Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.. <i>Blood</i> , 2004, 104, 2747-2747.	1.4	10
139	Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. <i>Leukemia Research</i> , 2004, 28, 1153-1157.	0.8	9
140	Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with T Cell Lymphomas Participating in the PETAL Trial. <i>Blood</i> , 2016, 128, 185-185.	1.4	9
141	Differential Expression of bcl-2 and Susceptibility to Programmed Cell Death in Lymphocytes of HIV-1-Infected Individuals. <i>Clinical Immunology and Immunopathology</i> , 1998, 87, 230-239.	2.0	8
142	Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34+ cells selected from patients with both low- and high-risk myelodysplastic syndrome. <i>Experimental Hematology</i> , 2010, 38, 718-732.e6.	0.4	8
143	Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. <i>Medicina Clínica</i> , 2011, 136, 323-328.	0.6	8
144	Dexamethasone Dose and Schedule Significantly Influences Remission Rate and Toxicity of Induction Therapy in Adult Acute Lymphoblastic Leukemia (ALL): Results of the GMALL Pilot Trial 06/99.. <i>Blood</i> , 2005, 106, 1832-1832.	1.4	8

#	ARTICLE	IF	CITATIONS
145	Inhibition of Phosphotyrosine Phosphatase-1B (PTP1B) Induces Resistance to the ABL Kinase Inhibitor Imatinib Mesylate (Gleevec®) in BCR-ABL Positive Leukemic Cells.. Blood, 2004, 104, 2095-2095.	1.4	8
146	Monitoring and Managing Minimal Residual Disease in Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 290-293.	3.8	7
147	Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases. Blood, 2018, 132, 660-660.	1.4	7
148	“Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions” Treatment of ALL. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 301-310.	0.4	6
149	Mechanism of T-Cell-Mediated Inhibition of Stem Cell Differentiation in Vitro: Possible Relevance for Myelosuppression in HIV-Infected Individuals. Cellular Immunology, 1998, 184, 26-36.	3.0	5
150	Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. Advances in Therapy, 2019, 36, 870-879.	2.9	4
151	Fludarabine Versus Fludarabine Plus Epirubicin in the Treatment of Chronic Lymphocytic Leukemia - Final Results of a German Randomized Phase-III Study.. Blood, 2005, 106, 2123-2123.	1.4	4
152	Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 5340-5340.	1.4	4
153	Minimal Residual Disease and Mutational Status Prior to and after SCT for Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 2008, 112, 702-702.	1.4	4
154	CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia. Cancer, 2013, 119, 2671-2674.	4.1	3
155	Clinical Applications and Pitfalls of MRD in ALL. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S9-S11.	0.4	2
156	Developing a European network for adult ALL. The Hematology Journal, 2004, 5, S46-S52.	1.4	2
157	In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission. Blood, 2013, 122, 231-231.	1.4	2
158	Long-Term Follow-Up of Patients Treated by Gene Therapy for X-Linked Chronic Granulomatous Disease.. Blood, 2005, 106, 194-194.	1.4	1
159	HOX11L2 Genotyping Identifies Subset of Adult Thymic T-ALL with Inferior Outcome.. Blood, 2005, 106, 228-228.	1.4	1
160	Acute lymphoblastic leukemia in adults. , 2009, , 43-53.		0
161	Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia. , 2013, , 331-354.		0
162	Burkitt Lymphoma. , 2013, , 231-242.		0

#	ARTICLE	IF	CITATIONS
163	Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia. , 2018, , 337-357.		0
164	Significant Down-Regulation of BAALC during Lineage Specific Hematopoietic Differentiation.. Blood, 2004, 104, 4189-4189.	1.4	0
165	CD10 ⁺ Pre-B Acute Lymphoblastic Leukemia (ALL): A Distinct High-Risk Subgroup of Adult ALL.. Blood, 2005, 106, 1443-1443.	1.4	0
166	Measurement of Minimal Residual Disease (MRD) after Consolidation Therapy as a Means of Early Detection of Relapse in Adult Acute Lymphoblastic Leukemia (ALL).. Blood, 2005, 106, 538-538.	1.4	0
167	Prostate-Apoptosis-Response-Gene-4 Increases Sensitivity to TRAIL-Induced Apoptosis.. Blood, 2005, 106, 2485-2485.	1.4	0
168	Insertional Activation of MDS1/EVI1, PRDM16 and SETBP1 in a Successful Chronic Granulomatous Disease (CGD) Gene Therapy Trial.. Blood, 2006, 108, 3274-3274.	1.4	0
169	The Identification of ERG Related Pathways Pinpoints to Mechanisms Implicated in the Inferior Outcome of Acute T-Lymphoblastic Leukemia (T-ALL) with High ERG Expression.. Blood, 2006, 108, 1828-1828.	1.4	0
170	Identification of Novel Recurrent Genomic Aberrations by Array-CGH in Adult Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 4476-4476.	1.4	0
171	MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.. Blood, 2007, 110, 2799-2799.	1.4	0
172	The Clonal Inventory of Gene Corrected Hematopoiesis in Three Successful Clinical Gene Therapy Trials. Blood, 2007, 110, 3733-3733.	1.4	0
173	Low Expression of IL-15 in Adult B-Lineage Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement at Initial Presentation.. Blood, 2007, 110, 2389-2389.	1.4	0
174	Overexpression of BAALC Indicates Drug Resistance and Inferior Survival in Adult B-Precursor Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 1581-1581.	1.4	0
175	Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 2041-2041.	1.4	0
176	Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL-Negative Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2617-2617.	1.4	0
177	Treatment of Lymphoblastic Lymphoma in Adults. , 2008, , 203-214.		0